Monday, 28 May 2018

You are here

Gout Crystal Deposition is Deeper than its Measures

Dalbeth and colleagues have published that among gout patients without palpable tophic and despite long term allopurinol, nearly half have monosodium urate (MSU) as detected by Dual-energy CT (DECT).  The total body urate deposition is even greater in those with higher sUA and evidence of severe disease. 

They enrolled 152 gout patients from New Zealand and USA who were receiving allopurinol ≥300 mg/day for a mean of 5.1 years. MSU crystal deposition was assessed b DECT in the hands/wrists, feet/ankles/Achilles and knees and correlated with sUA levels and gout characteristics.

  • Among allopurinol treated patients, 69.1% had crystal deposition on DECT, with a median total crystal volume of 0.16 cm3.
  • Crystal deposition was found in 46.9% of patients with sUA <6.0 mg/dL and no palpable tophi
  • Crystal deposition was found in 90.0% among those with sUA ≥6.0 mg/dL and tophi.
  • Total volume of crystal deposition was positively associated with sUA ≥6.0 mg/dL, gout flares, tophi and the patients global disease activity scores.

These data are sobering, given the fact that only 30-45% of treated gouty patients will achieve a treat-to-target goal of sUA <6.0 mg/dl. Nearly half of the patients who achieve that goal in this cohort study still had tissue MSU crystal deposition.  

Gout runs deeper than the tophi and is more sinister than the serum urate level measured.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The Hazardous Highs and Lows of Uric Acid

Both high and low levels of uric acid were linked with increased risks of death, showing a U-shaped association between serum uric acid levels and all-cause, cardiovascular, and cancer mortality, Korean researchers reported.

Unmet Needs in Calcium Pyrophosphate Deposition Disease

Abhishek et al have written on the results of an international survey of crystal arthritis experts and identified the unmet needs  regarding calcium pyrophosphate crystal deposition (CPPD) - research, classification, diagnosis and management.

CPPD is a highly prevalent condition with a range of manifestations that may lead to pain, synovitis and joint damage, especially in the elderly.

FIELD Study: Fenofibrate Reduces Uric Acid and Gout Risk

Lancet reports the results of the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study - where fenofibrate was shown to reduce uric acid by 20%, gout events by nearly 50% and may be useful in preventing gout in diabetes. 

In the study, 9795 adults (age 50–75 years) with type 2 diabetes were randomized to receive fenofibrate 200 mg per day or placebo and followed for up to 5 years.

Time to Rethink Gout as a Chronic Disease

The current issue of JAMA has a perspective article on Gout’s bad rap as dietary disease rather than the complex, chronic inflammatory disorder that is ineffectively treated in many. 

The author and experts interviewed believe that the pipeline of new drugs for gout will fuel the future of evidence-based care and more informed lifestyle instruction.

Does Dose Escalation Help in Gout?

Contrary to expectations, dose escalation of allopurinol among patients with gout did not improve survival, a 10-year observational study found.